Abstract Cytochrome P450 2C19 (CYP2C19) is the main (or partial) cause for large
differences in the pharmacokinetics of a number of clinically important drugs. On the basis of …

The proton pump inhibitors rabeprazole, omeprazole, lansoprazole, and pantoprazole
undergo an extensive hepatic biotransformation. In the liver, they are metabolized to varying …

Cytochrome P450 phenotyping provides valuable information about real-time activity of
these important drug-metabolizing enzymes through the use of specific probe drugs. Despite …

The isoenzymes which catalyse the polymorphic hydroxylations of debrisoquine/sparteine
and S-mephenytoin are cytochromes P450 2D6 and P450 2C19 (CYP2D6 and CYP2C19) …

Introduction: The frequency of CYP2D6 alleles, related to either a lack of or increased
enzymatic activity, which may lead to poor metabolism (PM) or ultrarapid metabolism (UM) …

The present study evaluates the worldwide frequency distribution of CYP2C19 alleles and
CYP2C19 metabolic phenotypes ('predicted'from genotypes and 'measured'with a probe …

Objectives: The purpose of this pharmacokinetic study was to investigate the dose-
dependent inhibition of model substrates for CYP2D6, CYP2C19 and CYP1A2 by four …

Ultrarapid Hydroxylation of Debrisoquine in a Swedish Population. Analysis of the
Molecular Genetic Basis1 Page 1 vol. No. 1 Printed in USA ABSTRACT ABBREVIATIONS …

European data on the polymorphic metabolism of debrisoquine, sparteine,
dextromethorphan and mephenytoin have been collected. No significant difference in …

Response to drugs can vary between individuals and between different ethnic populations.
The biological (age, gender, disease and genetics), cultural and environmental factors …